Publication date: Feb 03, 2025

The concentrations of 135 pharmaceuticals and personal care products (PPCPs) were determined in raw influent, final effluent, and treated biosolids at Canadian wastewater treatment plants (WWTPs) to evaluate the fate of PPCPs through liquid and solids trains of typical treatment types used in Canada and to assess changes in PPCP concentrations in wastewater matrices between 2010-2013 and 2022. PPCPs dominant in influent and effluent included the antidiabetic metformin, analgesics/anti-inflammatories (acetaminophen, ibuprofen, 2-hydroxy-ibuprofen), caffeine and its metabolite (1,7 - dimethylxanthine), theophylline (a bronchodilator and metabolite of caffeine), an insect repellent (N,N-diethyl-m-toluamide, DEET), and iopamidol (a contrast media for X-rays). PPCPs dominant in biosolids differed from those in influent/effluent and included antibiotics (fluoroquinolones and doxycycline), antidepressants (sertraline, citalopram, and amitriptyline), a preservative and antimicrobial agent (triclosan), an antihistamine (diphenhydramine), and an antifungal (clotrimazole). These elevated concentrations in influent/effluent and biosolids reflected their use in Canadian communities. PPCPs dominant in influent/effluent had relatively low hydrophobicity whereas those in biosolids tended to be more hydrophobic, or electrostatic forces governed their sorption. Higher removal of PPCPs was generally observed at WWTPs that used biological treatment compared to primary physical/chemical treatment. PPCP concentration changes in wastewater matrices between 2010-2013 and 2022 were influenced by risk management measures, warnings, the development of new pharmaceuticals, the COVID-19 pandemic, and other factors. These time trends reflected the limited information available on PPCP use in Canada. Continued periodic monitoring of PPCPs is recommended to fill data gaps on community use and release to the environment.

Open Access PDF

Semantics

Original Article